UNSPSC 51281912: Puromycin aminonucleoside

This classification denotes a protein synthesis inhibitor and miscellaneous antineoplastic antibiotic with the molecular formula C12H18N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Q580U88V8, chemically known as 6-(dimethylamino)-9-(3-amino-3-deoxy-.beta.-d-ribofuranosyl)purine, but more generally known as puromycin aminonucleoside, which bears US NIH Compound Identifier 1599.

European Medicines Agency schedules puromycin aminonucleoside or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10161MIG. Most nations, for tariff purposes, schedule puromycin aminonucleoside under HS 29419000. SMILES: CN(C)C1C2C(NCN1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O.

UNSPSC 51281912 Puromycin aminonucleoside, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The single recent opportunity is a Texas Health and Human Services Commission Request for Information (RFI No. HHS0017013, posted April 3, 2026) that solicits vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a procurement mechanism focused on pharmaceutical distribution channels and contracting relationships rather than the procurement of puromycin aminonucleoside itself as a finished pharmaceutical product. The RFI seeks information from vendors capable of establishing direct relationships between the state's pharmacy benefit program and manufacturers, emphasizing experience with self-insured employer and health plan contracting, negotiated net pricing models, and value-based or outcomes-based agreements. No formal evaluation criteria, site visit requirements, bidders' meetings, award values, or budget ranges are specified in the RFI materials, as this represents a preliminary market intelligence phase designed to inform future formal solicitations.

The code shows activity only in Texas, with no geographic spread across multiple jurisdictions in recent records. The issuing body is the Texas Health and Human Services Commission, a state-level health agency rather than a county, city, school district, or transit authority. The RFI is exploratory rather than a binding competitive solicitation — it does not commit the state to specific contract amounts, durations, or vendor selection timelines, and completion of this information-gathering phase will likely precede a formal Request for Proposal (RFP) with established financial and temporal parameters.